



(R)

To,
Department of Corporate Service
BSE Limited,
Registered Office : Floor 25, P. J. Towers,
Dalal Street, Fort, Mumbai 400001. MAHARASHTRA.
T: 2272 1233 / 1234 | F : 2272 3121 / 3719 | www.bseindia.com

Thursday, November 13, 2025

Subject : Approval of Standalone Un-Audited Financial Results for the quarter and half year ended September 30, 2025.

Reference : CENTENIAL SURGICAL SUTURE LTD. | Scrip Code: 531380

Sir,

In pursuance of Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby submit following documents:

- 1). Standalone Un-Audited Financial Results for the quarter and half year ended September 30, 2025.
- 2). Statement of Assets and Liabilities for the half year ended September 30, 2025.
- 3). Cash Flow Statement for the half year ended September 30, 2025.
- 4). Limited Review Report for the quarter and half year ended September 30, 2025.

The said meeting commenced at 06:00 p.m. and concluded at 06:25 p.m. Kindly take the same on your record.

Sincerely,

For **CENTENIAL SURGICAL SUTURE LTD.**



Mahima Bathwal Digitally signed by
Mahima Bathwal
Date: 2025.11.13
18:29:12 +05'30'

Mahima BATHWAL
Membership No. ACS A35069
Company Secretary & Compliance Officer

Enclosures : as mentioned above.



ISO
9001:2015

ISO
13485:2016

ISO
14001:2015

ISO
45001:2018

W.H.O.
G.M.P.




CONTINUATION
SHEET

Statement of Standalone Un-Audited Financial Results for the Quarter and Half year ended September 30, 2025

(Rs. In Lakhs, unless otherwise stated)

Sr. No.	Particulars	Quarter ended			Half Year ended		Year ended
		30/09/2025	30/06/2025	30/09/2024	30/09/2025	30/09/2024	31/03/2025
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
I	Revenue from Operations	1345.50	1293.61	1427.24	2639.11	2800.97	5,351.62
II	Other Income	4.91	0.19	6.48	5.10	6.51	12.01
III	Total Revenue (I + II)	1350.41	1293.80	1433.72	2644.21	2807.48	5363.63
IV	Expenses :						
	(a) Cost of Material Consumed	417.94	506.75	408.78	924.70	945.80	1656.38
	(b) Purchase of Stock-in-Trade	-	-	-	-	-	-
	(c) Changes in Inventories of Finished Goods, Work-in-Progress & Stock-in-Trade	28.85	(74.11)	152.92	(45.26)	98.61	66.42
	(d) Employee Benefits Expenses	315.42	274.53	279.73	589.94	562.17	1185.86
	(e) Finance Cost	46.20	31.78	52.52	77.98	105.57	374.55
	(f) Depreciation and Amortisation Expenses	99.26	95.14	109.22	194.40	188.45	425.46
	(g) Other Expenses	443.94	463.62	413.64	907.56	850.13	1816.73
	Total Expenses (IV)	1351.61	1297.71	1416.81	2649.32	2750.73	5525.40
V	Profit / (Loss) before Exceptional items and Tax (III - IV)	(1.20)	(3.91)	16.91	(5.11)	56.75	(161.78)
VI	Exceptional Items	-	-	-	-	-	-
VII	Profit / (Loss) Before Tax (V - VI)	(1.20)	(3.91)	16.91	(5.11)	56.75	(161.78)
VIII	Tax Expense :						
	(1) Current Tax	-	-	4.25	-	14.28	-
	(2) Deferred tax	-	-	-	-	-	(15.41)
	Total Tax Expenses	-	-	4.25	-	14.28	(15.41)
IX	Profit / (Loss) for the period from Continuing Operations (VII - VIII)	(1.20)	(3.91)	12.66	(5.11)	42.47	(146.37)
X	Profit / (Loss) from Discontinued Operations	-	-	-	-	-	-
XI	Tax expenses of Discontinued Operations	-	-	-	-	-	-
XII	Profit / (Loss) From Discontinuing Operations (after tax) (X-XI)	-	-	-	-	-	-
XIII	Profit / (Loss) for the period* (IX+XII)	(1.20)	(3.91)	12.66	(5.11)	42.47	(146.37)
XIV	Other Comprehensive Income						
	A. (i) Items that will not be reclassified to profit or loss	-	-	-	-	-	-
	(ii) Income tax relating to items that will not be reclassified to profit or loss	-	-	-	-	-	-
	B. (i) Items that will be reclassified to profit or loss	-	-	-	-	-	-
	(ii) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-	-	-
XV	Total Comprehensive Income for the period (XIII + XIV) (comprising Profit / (Loss) for the period after tax and Other Comprehensive Income after tax)	(1.20)	(3.91)	12.66	(5.11)	42.47	(146.37)
XVI	Earnings Per Equity Share (for Continuing operation) :						
	(a) Basic	(0.03)	(0.11)	0.35	(0.14)	1.16	(4.01)
	(b) Diluted	(0.03)	(0.11)	0.35	(0.14)	1.16	(4.01)
XVII	Earnings Per equity share (for Discontinued operation) :						
	(a) Basic	-	-	-	-	-	-
	(b) Diluted	-	-	-	-	-	-
XVIII	Earnings Per Equity Share (for Discontinued & Continuing operation):						
	(a) Basic	(0.03)	(0.11)	0.35	(0.14)	1.16	(4.01)
	(b) Diluted	(0.03)	(0.11)	0.35	(0.14)	1.16	(4.01)



Vijay MAJREKAR
Managing Director
CENTENIAL
SURGICAL SUTURE LTD.
REGD. OFF. : F-29, MIDC, MURBAD, THANE 421401
MAHARASHTRA



ISO
9001:2015

ISO
13485:2016

ISO
14001:2015

ISO
45001:2018

W.H.O.
G.M.P.




(R)

Notes:


- 1). This Standalone Un-Audited Financial Results was reviewed and recommended by the Audit Committee of the Company and subsequently approved by the Board of Directors at their respective meetings held on November 13, 2025.
In accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015, the Statutory Auditors of the Company have carried out a Limited Review of this Standalone Un-Audited Financial Results for the quarter and half-year ended September 30, 2025.
- 2). The Company has one reportable business segment "Medical Devices".
- 3). The Company's Operation consists only one segment; hence Segment reporting under AS17 is not applicable.
- 4). Previous year figures have been regrouped or reclassified wherever necessary.
- 5). There is no proceeds of public issue, rights issue, preferential issue, qualified institutions placement, etc., therefore statement on the same is not forming part of this results.
- 6). There are no outstanding defaults on loans and debt securities, therefore statement on the same is not forming part of this results.
- 7). As per the Master Circular dated November 11, 2024 company is not required to give disclosure as per B and C point as not applicable for the current quarter.
- 8). The Standalone Un-Audited Financial Results for the Quarter ended September 30, 2025 are available on the website of BSE Limited at www.bseindia.com and on Company's website at www.centenialindia.com.
- 9).

for and on behalf of the Board of Directors of
for **CENTENIAL SURGICAL SUTURE LTD.**



Vijay MAJREKAR
Managing Director ~ DIN : 00804808

Place : Mumbai, Maharashtra
Date : November 13, 2025





Statement of Assets and Liabilities


Rs. In Lakhs			
	Particulars	As at September 30, 2025 Unaudited	As at March 31, 2025 Audited
I	ASSETS		
1)	Non-current assets		
	a) Property, Plant and Equipment	1,716.19	1810.68
	b) Right to Use Assets	151.66	187.60
	c) Other Intangible assets	0.39	0.42
	d) Financial assets		-
	(i) Loans	-	-
	(ii) Other financial assets	46.76	46.81
	e) Deferred tax assets (net)	2.98	2.98
	f) Income-tax assets (net)	90.78	87.77
	g) Other non-current assets	25.82	25.82
	Total Non-current assets (1)	2,034.58	2,162.08
2)	Current assets		
	a) Inventories	4,168.38	4348.13
	b) Financial assets	-	
	(i) Trade receivables	1,984.92	1839.64
	(ii) Cash and cash equivalents	55.69	21.95
	(iii) Bank balances other than (ii) above	-	-
	(iv) Loans	-	-
	(v) Other current financial assets	-	-
	c) Other current assets	84.43	86.67
	Total Current assets (2)	6,293.42	6,296.39
	TOTAL ASSETS (I = 1 + 2)	8,328.00	8,458.47
II	EQUITY & LIABILITIES		
1)	Equity		
	a) Equity Share capital	542.43	542.43
	b) Other Equity	2,526.98	2,533.06
	Total Equity (1)	3,069.41	3,075.49
2)	Liabilities		
	Non-current liabilities		
	a) Financial Liabilities		
	(i) Other financial liabilities	2,151.80	2,200.03
	b) Long-term provisions	-	-
	c) Deferred tax liabilities (net)		
	Total Non-current liabilities	2,151.80	2,200.03
	Current liabilities		
	a) Financial Liabilities		
	(i) Trade payables	651.53	717.34
	(ii) Borrowings	1,081.06	1,225.78
	(iii) Other current financial liabilities	664.38	617.59
	b) Other current liabilities	709.82	622.25
	c) Short-term provisions	-	-
	Total Current liabilities	3,106.79	3,182.96
	Total Liabilities (2)	5,258.59	5,382.98
	TOTAL EQUITY AND LIABILITIES (II = 1 + 2)	8,328.00	8,458.47





Cash Flow Statement for the Quarter and Half Year ended September 30, 2025

Rs. In Lakhs		
Particulars	As at September 30, 2025 UNAUDITED	As at March 31, 2025 Audited
A. Cash flow from operating activities		
Net Profit before tax	(5.11)	(161.78)
Adjustments for :		
Depreciation and amortisation expense	194.40	425.46
Interest income	(0.57)	(4.04)
Finance Cost	77.98	374.55
Exchange gain	(4.53)	(7.96)
Provision for Leave encashment	-	-
Provision for Gratuity	25.82	25.82
Sundry balances written back/written-off	-	-
Operating profit before working capital changes	287.99	652.05
Adjustments for :		
Decrease / (Increase) in inventories	179.75	(96.59)
Decrease / (Increase) in trade receivable	(145.34)	40.80
Decrease / (Increase) in long term loans and advances and other receivables	-	-
Decrease / (Increase) in financials and non-financial assets	(0.85)	(27.77)
Decrease / (Increase) in other assets and receivables	2.24	244.74
(Decrease) / Increase in trade and other payables	20.32	920.67
Cash generated from operations	344.11	1733.90
Income tax refund / (paid)	(3.00)	(26.50)
Net cash (used in) / generated from operating activities	341.11	1707.40
B. Cash flow from investing activities		
Acquisition of fixed assets and capital work in progress	(63.94)	(1146.91)
Proceeds from sale of investments	-	-
Interest income on fixed deposits and other advances & exchange difference	(20.73)	(13.82)
Net cash (used in) / generated from investing activities	(84.67)	(1160.73)
C. Cash flow from financing activities		
Finance Cost	(77.98)	(374.55)
Proceeds from Short term borrowings	(144.72)	(218.64)
Net cash (used in) / generated from financing activities	(222.70)	(593.19)
Net (decrease) / increase in cash and cash equivalents (A+B+C)	33.74	(46.51)
Cash and cash equivalents as at the beginning of year	21.95	68.46
Cash and cash equivalents at the end of year	55.69	21.95
Components of cash and cash equivalents		
Cash in hand	3.23	1.72
Balance with scheduled banks in current accounts	52.46	20.23
Total	55.69	21.95



Vijay MAJREKAR
Managing Director
CENTENIAL
SURGICAL SUTURE LTD.
REGD. OFF. : F-29, MIDC, MURBAD, THANE 421401
MAHARASHTRA

Independent Auditor's Review Report on Standalone Un-Audited Financial Results of the Company for the Quarter ended September 30, 2025 pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements [LODR]) Regulations, 2015, as amended.

Review Report to

The Board of Directors of CENTENIAL SURGICAL SUTURE LTD.

Registered Office : F-29, M.I.D.C., Murbad, Thane 421401. MAHARASHTRA.

- a. We have reviewed the accompanying Statement of Standalone Unaudited Financial Results of **Centenial Surgical Suture Limited** (the "Company") for the quarter ended **September 30, 2025** ("the Statement") prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 (*Interim Financial Reporting*) ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 and relevant rules issued thereunder, and other accounting principles generally accepted in India, in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, and SEBI Circulars issued thereunder.
- b. This Statement, which is the responsibility of the Company's Management and approved by the Board of Directors at their meeting held on **November 13, 2025**, has been prepared in accordance with the recognition and measurement principles of Ind AS 34 and other applicable accounting standards and policies. The management is responsible for the maintenance of adequate accounting records, for safeguarding the assets of the Company, and for preventing and detecting fraud and other irregularities.
- c. Our responsibility is to issue a report on the Statement based on our review. We conducted our review in accordance with the Standard on Review Engagements (SRE) 2410, **Review of Interim Financial Information Performed by the Independent Auditor of the Entity**, issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of those responsible for financial and accounting matters, and applying analytical and other review procedures. It is substantially less in scope than an audit conducted in accordance with Standards on Auditing and accordingly, we do not express an audit opinion.
- d. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in Ind AS 34 and other accounting principles generally accepted in India, **does not disclose the information required to be disclosed** in terms of Regulation 33 of the SEBI (LODR) Regulations, 2015, as amended, including the manner in which it is required to be disclosed, or that it **contains any material misstatement**.

For **M/s. MAHESH CHANDRA & ASSOCIATES**

CHARTERED ACCOUNTANTS

[Firm Registration No.: 112334W]

ADITYAVIKRAM BOHRA
Digitally signed by
ADITYAVIKRAM BOHRA
Date: 2025.11.13
19:13:51 +05'30'

Adityavikram Bohra

Date : November 13, 2025

Partner

Place : Mumbai, MAHARASHTRA.

[Membership No.193223]
UDIN: 25193223BMLCLO2301